Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of oral EP262 in adults with chronic inducible urticaria
NL-OMON58972Phase 1Completed
- Sponsor
- Escient Pharmaceuticals
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of EP262 in chronic inducible urticaria (CIndU), sponsored by Escient Pharmaceuticals. Started Feb 2024; status: completed.
02
Drugs
EP262
03
Conditions
chronic inducible urticaria (CIndU)
Beyond the preview
Go deeper on NL-OMON58972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58972.